Plus Therapeutics Stock (NASDAQ:PSTV)
Previous Close
$1.24
52W Range
$0.93 - $2.67
50D Avg
$1.21
200D Avg
$1.56
Market Cap
$7.08M
Avg Vol (3M)
$76.89K
Beta
0.69
Div Yield
-
PSTV Company Profile
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
PSTV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HOTH | Hoth Therapeutics, Inc. |
| SRZN | Surrozen, Inc. |
| ADTX | Aditxt, Inc. |
| TARA | Protara Therapeutics, Inc. |
| VRAX | Virax Biolabs Group Limited |
| IMMX | Immix Biopharma, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| DRMA | Dermata Therapeutics, Inc. |
| REVB | Revelation Biosciences, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| ATXI | Avenue Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
| ENVB | Enveric Biosciences, Inc. |
| PALI | Palisade Bio, Inc. |